Janney Montgomery Scott LLC Buys Shares of 12,861 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Janney Montgomery Scott LLC purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 12,861 shares of the biotechnology company’s stock, valued at approximately $821,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Sarepta Therapeutics by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock worth $1,104,701,000 after buying an additional 117,904 shares during the last quarter. Capital International Investors raised its holdings in shares of Sarepta Therapeutics by 38.9% during the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares in the last quarter. Farallon Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 11.1% in the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after purchasing an additional 285,100 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in Sarepta Therapeutics by 0.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company’s stock worth $237,901,000 after purchasing an additional 10,343 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Sarepta Therapeutics by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company’s stock worth $207,538,000 after buying an additional 9,999 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock opened at $17.10 on Tuesday. The firm has a market cap of $1.68 billion, a P/E ratio of -6.36 and a beta of 0.61. The firm’s 50-day simple moving average is $38.71 and its 200-day simple moving average is $77.73. Sarepta Therapeutics, Inc. has a twelve month low of $16.96 and a twelve month high of $162.95. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The company had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. During the same period in the previous year, the firm posted $0.73 earnings per share. The firm’s revenue for the quarter was up 80.2% compared to the same quarter last year. As a group, research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SRPT has been the subject of a number of analyst reports. Robert W. Baird reduced their price target on Sarepta Therapeutics from $60.00 to $30.00 and set an “outperform” rating for the company in a research report on Tuesday, June 17th. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a report on Wednesday, June 25th. Oppenheimer dropped their price target on shares of Sarepta Therapeutics from $123.00 to $45.00 and set an “outperform” rating on the stock in a research report on Friday, June 20th. UBS Group reduced their price objective on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Finally, Bank of America reiterated a “neutral” rating and issued a $28.00 target price (down from $76.00) on shares of Sarepta Therapeutics in a research note on Monday, June 16th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $60.88.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.